NEW YORK (GenomeWeb News) – Presenting at an investors meeting in London this week, Roche said this week that is has more than 200 companion diagnostic projects ongoing across its pharma and diagnostics units. "More than 60 percent of our pharmaceutical pipeline projects are couples with the development of companion diagnostics in order to make treatments more effective," Roche CEO Severin Schwan said.

The firm also noted that approximately 50 percent of its R&D budget is allocated to oncology drugs and diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.